Integrated Filing (Finance) Ind AS

PARK MEDI WORLD LIMITED

General Information

Scrip code*	544645
NSE Symbol*	PARKHOSPS
MSEI Symbol*	NOTLISTED
ISIN*	INE119201023
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2026
Date of end of financial year	31-03-2027
Date of board meeting when results were approved	03-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	29-07-2026
Description of presentation currency	INR
Level of rounding	Millions
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	Healthcare Services
Start date of board meeting	03-08-2026
Start time of board meeting	08:00:00
End date of board meeting	03-08-2026
End time of board meeting	09:20:00
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results - Ind-AS

Amount in (Millions)

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2026	01-04-2026
Date of end of reporting period		30-06-2026	30-06-2026
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**		
1	**Income**		
	Revenue from operations	4,757.09	4,757.09
	Other income	76.46	76.46
	Total income	4,833.55	4,833.55
2	**Expenses**		
(a)	Cost of materials consumed	771.24	771.24
(b)	Purchases of stock-in-trade	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(8.67)	(8.67)
(d)	Employee benefit expense	924.07	924.07
(e)	Finance costs	98.10	98.10
(f)	Depreciation, depletion and amortisation expense	188.40	188.40
(g)	**Other Expenses**		
1	Professional and consultancy fees	756.05	756.05
2	Other expenses	1,053.52	1,053.52
	Total other expenses	1,809.57	1,809.57
	Total expenses	3,782.71	3,782.71
	Total profit before exceptional items and tax	1,050.84	1,050.84
4	Exceptional items	0.00	0.00
5	**Total profit before tax**	1,050.84	1,050.84
6	**Tax expense**		
7	Current tax	258.31	258.31
8	Deferred tax	(93.40)	(93.40)
9	**Total tax expenses**	164.91	164.91
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	**Net Profit Loss for the period from continuing operations**	885.93	885.93
12	Profit (loss) from discontinued operations before tax	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00
14	**Net profit (loss) from discontinued operation after tax**	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	**Total profit (loss) for period**	885.93	885.93
17	Other comprehensive income net of taxes	(5.81)	(5.81)
18	**Total Comprehensive Income for the period**	880.12	880.12
19	**Total profit or loss, attributable to**		
	Profit or loss, attributable to owners of parent	825.07	825.07
	Total profit or loss, attributable to non-controlling interests	60.86	60.86

20	**Total Comprehensive income for the period attributable to**		
	Comprehensive income for the period attributable to owners of parent	(5.69)	(5.69)
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	(0.12)	(0.12)
21	**Details of equity share capital**		
	Paid-up equity share capital	863.86	863.86
	Face value of equity share capital	2.00	2.00
22	Reserves excluding revaluation reserve		
23	**Earnings per share**		
i	**Earnings per equity share for continuing operations**		
	Basic earnings (loss) per share from continuing operations	2.05	2.05
	Diluted earnings (loss) per share from continuing operations	2.05	2.05
ii	**Earnings per equity share for discontinued operations**		
	Basic earnings (loss) per share from discontinued operations	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00
iii	**Earnings per equity share (for continuing and discontinued operations)**		
	Basic earnings (loss) per share from continuing and discontinued operations	2.05	2.05
	Diluted earnings (loss) per share from continuing and discontinued operations	2.05	2.05
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)	Notes to the unaudited Consolidated financial results for the quarter ended June 30, 2026: 1. The unaudited Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) - 34 "Interim Financial Reporting" notified under Section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standard Rules), 2015 (as amended from time to time) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). 2. The unaudited Consolidated financial results ('the Statement) of Park Medi World Limited ('the company') for the quarter ended June 30, 2026 were reviewed by the Audit committee on August 03, 2026 and approved by the Board of Directors at its meeting held on August 03, 2026 in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the statutory auditors of the company who have issued an unmodified opinion on the same. 3. The Company has launched a 350 bedded advanced multi-super specialty hospital at Panchkula on April 10, 2026. The Panchkula hospital is equipped with advanced diagnostics, modular operation theatres, critical care infrastructure, and will deliver comprehensive care across key specialties including oncology, neurosciences, orthopaedics, cardiology, and critical care including robotic-assisted procedures. 4. The Company has successfully acquired 80% shareholding of V3 Healthcare Private Limited on July 31, 2026 which operates a multi-super speciality Hospital in the name of "The Medicity Hospital - Rudrapur", Uttaranchal having capacity of 330 beds. Remaining 20% will be acquired by April 30, 2030. Overall cost of acquisition is approx. Rs. 1,770 millions. Consequent to this acquisition, V3 Healthcare Private Limited has become a subsidiary of the Company. Further, the Hospital has been launched on August 2, 2026. 5. RGS Healthcare Limited, the step down subsidiary of the Company, has proposed the expansion of its Mohali unit from 350 beds to 500 beds. The overall cost of expansion will be approx. Rs. 400 millions which is proposed to be funded through internal accruals. Umkal Healthcare Private Limited , the wholly owned subsidiary of the Company, has proposed the expansion of its existing 225-beded Park Hospital in Palam Vihar, Gurugram, with addition of 100 new beds. The newly expanded facility will be branded as "Park Hospital Platinum" and the proposed capacity addition is to be completed by November 2026. Overall cost of additional beds will be approx. Rs. 250 millions which is proposed to be funded from internal accruals. 6. Park Medicenters and Institutions Private Limited, a subsidiary of the Company, has incorporated a wholly owned subsidiary in the name of "Heal plus Medical Services Private

Limited" having CIN: U47721DC2026PTC471594, on May 20, 2026. The new subsidiary has not commenced business operations as of June 30, 2026, and hence has no financial impact on the consolidated results.

7. Aggarwal Hospital and Research Services Private Limited, a wholly owned subsidiary of the Company, has divested its entire 55% shareholding in Devina Derma Private Limited, a subsidiary of Aggarwal Hospital and Research Services Private Limited, for a consideration of INR 0.60 million. The transaction was completed on 05th June 2026 and since then Devina Derma Private Limited ceased to be a subsidiary of Aggarwal Hospital and Research Services Private Limited, and consequently, of the Company. This divestment has been undertaken by the company as a strategic management decision.

8. The Group's business activity primarily falls within a single reportable business segment namely "Healthcare Service" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind AS 108- "Segment Reporting". The Group does not distinguish revenues, costs and expenses between segments in its internal reporting, and report costs and expenses by nature as a whole. The Board of Directors (Chief Operating Decision Maker ("CODM")) reviews the Consolidated Financial information when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group operates and manages its business as a single segment mainly through the sale of healthcare services. The Group operates in one geographic segment namely "within India" and hence no separate information for geographic segment wise disclosure is required.

9. The utilisation of the IPO proceeds is summarised below:

Object of the issue as Utilisation planned Utilised up to Amount pending for utilisation
per prospectus: as per prospectus June 30, 2026 as on June 30, 2026

Repayment/ prepayment, in full 3,800.00 3,800.00 -
or in part, of outstanding borrowings
availed by our Company and our
Subsidiaries

Funding capital expenditure for 605.00 195.19 409.81
development of new hospital by our
Subsidiary Park Medicity (NCR)
Private Limited

Funding capital expenditure for 274.59 36.08 238.51
purchase of medical equipment by
our Company and our Subsidiaries,
Blue Heavens Healthcare Private
Limited and Ratnagiri Innovations
Private Limited

Unidentified inorganic acquisitions 2,453.18 2,453.18 -
and general corporate purposes

Total 7,132.77 6,484.45 648.32

	Issue expenses towards IPO 567.23 567.23 - Grand Total 7,700.00 7,051.68 648.32 There is no deviation in the utilization of proceeds from the objects stated in the offer document and there is no variation in the terms of contract referred to in the prospectus. 10. During the quarter ended June 30, 2026 the Company did not receive any investor complaint. No complaints were pending resolution as on June 30, 2026. The Company has adequate systems and processes in place to address investor grievances in a timely manner in compliance with Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015. 11. Previous period figures have been regrouped / reclassified wherever necessary to conform to current period classification and rounding off errors have been ignored. 12. The unaudited Consolidated financial results for the quarter ended June 30, 2026 are available on the Company's website at www.parkhospital.in and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com, where the shares of the Company are listed.

Other Comprehensive Income

Amount in (Millions)

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026	01-04-2026
	Date of end of reporting period	30-06-2026	30-06-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]		
1	**Amount of items that will not be reclassified to profit and loss**		
1	Remeasurement of employee defined benefit plans	(7.76)	(7.76)
	Total Amount of items that will not be reclassified to profit and loss	(7.76)	(7.76)
2	Income tax relating to items that will not be reclassified to profit or loss	(1.95)	(1.95)
3	**Amount of items that will be reclassified to profit and loss**		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	(5.81)	(5.81)

Details of Impact of Audit Qualification

Whether results are audited or unaudited	Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Auditor's opinion	
Declaration pursuant to Regulation 33(3)(d) of SEBI(LODR) Regulation, 2015:The company declares that its Statutory Auditor / s have issued an Audit Report with unmodified opinion for the period on Consolidated results	Yes

Sr.No	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Agiwal and Associates	Yes	28-02-2029

Audit qualification

<table>
<tr><th rowspan="2">Sr.</th><th rowspan="2">Details of Audit Qualification</th><th rowspan="2">Type of Audit Qualification</th><th rowspan="2">Frequency of qualification</th><th>For Audit Qualification(s) where the impact is quantified by the auditor</th><th colspan="3">For Audit Qualification(s) where the impact is not quantified by the auditor</th></tr>
<tr><th>Management's Views</th><th>(i) Management's estimation on the impact of audit qualification</th><th>(ii) If management is unable to estimate the impact, reasons for the same</th><th>Auditors Comments on (i) or (ii) above</th></tr>
<tr><td colspan="8">No records available</td></tr>
</table>